The second phase of the study will include about 300 participants who have already received two doses of the vaccine.
The Modern pharmaceutical company announced this Wednesday that it has begun clinical trials in the second phase of its study of a booster dose of its specific vaccine to combat the omicron variant of covid-19.
In a statement, Moderna explained that the second phase of the study will include, on the one hand, about 300 participants who have already received two doses of the vaccine and, on the other hand, another 300 subjects with the full schedule and a booster dose.
On the other hand, on the effectiveness of the current vaccine, Moderna indicated that according to a study, the neutralization of omicron six months after the third dose of 50 micrograms of the mRNA-1273 vaccine decreased, but remained detectable in all participants in the test. .
“We are reassured by the persistence of antibodies against omicron six months after the currently authorized booster of 50 micrograms of mRNA-1273,” stressed the pharmaceutical company’s chief executive, Stéphane Bancel, who highlighted the importance of a booster specifically targeting omicron for the threat long-term evidenced by the variant of evading immune defenses.
According to data published by The New England Journal of Medicine, 29 days after receiving the booster dose of Moderna against covid, there was a decline of up to 6.3 times in the neutralization of the omicron variant with respect to its maximum capacity, although antibodies were still detected in all participants.
This neutralization only decreased 2.3 times when it came to the original strain of the virus.
Pharmaceutical companies Pfizer and BioNTech announced on Tuesday the start of a clinical trial of a modified Covid-19 vaccine that could protect against the omicron variant of the coronavirus.
The statement from these two firms indicates that the initial results of the study, which will include 1,420 volunteers aged between 18 and 55, are expected to be available in the first half of this year.
“We continue to maintain an open dialogue with health authorities about an updated vaccine and ongoing data on the currently available vaccine, including what authorities require,” Pfizer said in a message. (I)
Paul is a talented author and journalist with a passion for entertainment and general news. He currently works as a writer at the 247 News Agency, where he has established herself as a respected voice in the industry.
